Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
复制标题
DOI：
10.1186/s13045-016-0283-0
复制
发表时间：
2016-06-30
影响因子：
28.5
通讯作者：
Wang ML
中科院分区：
文献类型：
--
作者：
Sanchez L;Wang Y;Siegel DS;Wang ML
Daratumumab是一种针对CD38的人类单抗，CD38是一种在多发性骨髓瘤(MM)细胞上过度表达的细胞表面蛋白。临床前研究表明，Daratumab通过多种机制诱导MM细胞死亡，包括补体依赖细胞毒(CDC)、抗体依赖细胞介导的细胞毒作用(ADCC)、抗体依赖细胞吞噬作用(ADCP)和细胞凋亡。在临床试验中，由于daratumumab令人鼓舞的疗效和可接受的安全性，daratumumab已经成为治疗骨髓瘤的一种新的选择，并成为第一个被FDA批准用于治疗MM的单抗。
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.